ArticleCancer research2007
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.
Article in Cancer research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.Journal of hematology & oncology · 2025Trial
- Non-cytotoxic functions of CD8 T cells: "repentance of a serial killer".Frontiers in immunology · 2022Review
- Article
- A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies.Mucosal immunology · 2020Article
- Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.Nature protocols · 2018Article
- Article
- Article
- Engagement of SLAMF2/CD48 prolongs the time frame of effective T cell activation by supporting mature dendritic cell survival.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Therapeutic cancer vaccines and combination immunotherapies involving vaccination.ImmunoTargets and therapy · 2014Review
- Helper cell-independent antitumor activity of potent CD8Oncoimmunology · 2013Article
- Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.Expert review of vaccines · 2013Review
- Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.Frontiers in immunology · 2013Article
- P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties.Frontiers in immunology · 2012Article
- Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Immunologic research · 2011Article
- Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.Cancer immunology, immunotherapy : CII · 2011Article
- Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines.Cancer immunology, immunotherapy : CII · 2009Article
- Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.Future oncology (London, England) · 2009Review
- Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
In contrast to the well-established efficacy of preventive vaccines, the effectiveness of therapeutic vaccines remains limited. To develop effective vaccination regimens against cancer, we have analyzed the effect of effector and memory CD8+ T cells on the ability of dendritic cells to mediate the immunologic and antitumor effects of vaccination. We show that in contrast to effector CD8+ T cells that kill antigen-carrying dendritic cells, IFNgamma-producing memory CD8+ T cells act as "helper" cells, supporting the ability of dendritic cells to produce interleukin-12 (IL-12) p70. Promoting the interaction of tumor antigen-carrying dendritic cells with memory-type "heterologous" (tumor-irrelevant) CD8+ T cells strongly enhances the IL-12p70-dependent immunogenic and therapeutic effects of vaccination in the animals bearing established tumors. Our data show that the suppressive and helper functions of CD8+ T cells are differentially expressed at different phases of CD8+ T-cell responses. Selective performance of helper functions by memory (in contrast to effector) CD8+ T cells helps to explain the phenomenon of immune memory and facilitates the design of effective therapeutic vaccines against cancer and chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.